# INAVO120 (NCT04191499)

> A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04191499
- Phase: PHASE2, PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Hoffmann-La Roche
- Conditions: Breast Cancer
- Interventions: Inavolisib; Placebo; Palbociclib; Fulvestrant
- Enrollment: 325
- Primary outcome: Progression-Free Survival (PFS)

## Commentary we found

- X threads: 114
- YouTube: 59
- Podcasts: 49
- X videos: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=inavo120-nct04191499

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04191499", "email": "<work email>"}; the inbox owner confirms by the emailed link.